medicine

Tempus AI Inc. (NASDAQ:TEM), an artificial intelligence-powered precision medicine solutions provider, which was listed on exchanges in June 2024 has seen major funds investing in the company during the fourth quarter of the year. What Happened: Tempus AI provides a two-pronged approach to...

Strategists are formulating counter-messages for Republicans against President Joe Biden‘s plan to negotiate Medicare drug prices, arguing that it could stifle innovation and lead to price controls, Politico reported. The GOP’s reframing of the drug pricing debate comes as Democrats...

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced earlier this week an agreement with Dr. Reddy's Laboratories Ltd (NYSE: RDY) to acquire its exclusive license of E7777, a late-stage oncology immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare form of non-Hodgkin...

Entera Bio Ltd (NASDAQ: ENTX) shares rallied higher Wednesday after the company announced it saw positive results from its final six-month bone mineral density results from the completed Phase 2 clinical trial of EB613 for osteoporosis. The company states that its EB613 is positioned to be the...

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ: BIIB) stock earlier this month when its Alzheimer's treatment Aduhelm was approved. Details on key catalytic events...

Clover Health Investments Corp (NASDAQ: CLOV) has been chosen by the Centers for Medicare and Medicare Services (CMS) to participate in Direct Contracting (DC) across 10 states. While the news is not surprising, the program’s official launch is positive for the company, according to BofA...

Moderna, Inc. (NASDAQ: MRNA), which shot to prominence with its coronavirus vaccine program, is beefing up its research and development team. What Happened: Jonathan Hoggatt, who was a principal faculty member at Harvard Stem Cell Institute, has joined Cambridge, Massachusetts-based Moderna...

A Brazilian medical education company is tapping the IPO market this week. The IPO Terms Afya has filed to offer 13.74 million Class A common shares in an IPO, with 11.83 million shares to be sold by the company and the remaining 1.92 million shares by selling shareholders, according to the F-1/A...

For all the talk and, yes, hype about the marijuana industry's so-called “green rush,” the big pharmaceutical companies appeared to be giving cannabis-based treatments the cold shoulder because of federal laws outlawing marijuana. Given the legal, political and cultural inroads...

Companies producing so-called “plantibodies,” or plant-produced antibodies created by genetic engineering, have been attracting headlines recently. San Diego-based Mapp Pharmaceutical, which was acquired last year by Allergan (NYSE: AGN), has gotten global attention over the...

We’re waist-deep into the earnings season, and many companies have already filed. The U.S. biotech firm Celgene Corp (NASDAQ: CELG) has filed as well, and its reported earnings beat Wall Street’s expectations. Here are some takeaways from the report. Earnings Overview Revenues...

Merck (NYSE: MRK) is a blue chip "Big Pharma" stock that is up for the last week, month, quarter, six months and year of market action. For 2014, Merck has risen by nearly 19 percent. There are three reasons for long-term investors to buy shares of Merck in expectation that the share...

The health care sector has been on fire in 2014, as investors continue to bet on the development of new drugs and increased need for medical services. On Tuesday, the pharmaceuticals industry received a vote of confidence, after both Pfizer Inc (NYSE: PFE) and Merck & Co. (NYSE: MRK)...

Short interest can be a very telling component of investor and trader sentiment toward a stock. High or rising short interest typically means that investors and traders believe a stock is going to drop or continue a current decline further. However, high short interest can also be viewed as a...

Mixed news came out this week on research into Alzheimer's.   New studies suggest the rate of Alzheimer's and other forms of dementia is dropping in the United States and other developed countries. Meanwhile, Big Pharma's years-long battle to find a treatment, if not a cure,...